Drug reference

viloxazine

NET Blocker, 5HT2B Receptor Antagonist, 5HT2C Receptor Agonist · ADHD treatment, Antidepressant

NET Blocker, 5HT2B Receptor Antagonist, 5HT2C Receptor AgonistADHD treatment, Antidepressant

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

—

not curated

Mechanism

Originally thought to be a norepinephrine transporter (NET) blocker, it has more recently been determined to act as an antagonist of the 5HT2B receptor and as an agonist of the 5HT2C receptor.

Indications

Attention-deficit/hyperactivity disorder (ADHD)Depression

Related guidelines

Depression in adults

IPS · Psychiatry · 2023

Beta-blockers in hypertension

MOHFW · Cardiology · 2024

Alcohol use disorder

MOHFW · Psychiatry · 2021

Hypertensive disorders of pregnancy

FOGSI · Obstetrics & Gynaecology · 2019

Depression in adults

NICE · Psychiatry · 2022

Ask House about viloxazine

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspace Ask House about this drug

Textbook-sourced·Sources: Goodman & Gilman 14e·Updated: 2026-05-10